Emerging Therapies Transform Waldenström Macroglobulinemia
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Asher Chanan-Khan, MD, Mayo Clinic, Jacksonville, Florida, discusses recent advances in Waldenström’s macroglobulinemia including developments in BTK inhibitors, BCL2 combinations, and novel targeted therapies.
Dr Chanan-Khan emphasizes the expanding role of immunotherapy and targeted approaches that are delivering high response rates and durable remissions, even in heavily pretreated patients. These findings signal a shift toward more effective, less chemotherapy-dependent strategies in Waldenström’s macroglobulinemia.
Source:
Chanan-Khan A. Waldenström’s macroglobulinemia management: What’s new and what’s next. Presented at Lymphoma, Leukemia & Myeloma Winter Symposium; January 30 - February 1, 2026. Amelia Island, Florida.
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
